Ionis Pharmaceuticals Inc (IONS)

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.

- Recordati brings deep rare disease expertise and proven capabilities in commercialization, access and country-specific regulatory environments...

Form 8-K - Current report

TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)

– Proven to deliver significant and robust triglyceride reductions – – Only treatment for sHTG indicated to...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities